Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 4
1999 4
2000 2
2001 1
2002 3
2003 4
2004 1
2006 2
2007 2
2008 3
2009 3
2010 4
2011 7
2012 9
2013 3
2016 1
2017 2
2018 1
2019 2
2021 4
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.
Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K. Gross-Goupil M, et al. Among authors: blot e. Eur J Cancer. 2012 Mar;48(5):721-7. doi: 10.1016/j.ejca.2012.01.011. Epub 2012 Feb 6. Eur J Cancer. 2012. PMID: 22317952 Review.
Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT.
Guigay J, Chamorey E, Lefebvre G, Rotarski M, Wagner JP, Blot E, Alfonsi M, Seronde A, Schulten J, Peyrade F, Le Tourneau C. Guigay J, et al. Among authors: blot e. Cancer Rep (Hoboken). 2022 Feb;5(2):e1467. doi: 10.1002/cnr2.1467. Epub 2021 Jun 22. Cancer Rep (Hoboken). 2022. PMID: 34156166 Free PMC article. Clinical Trial.
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky MC, Sire C, Blot E, Debourdeau P, Bozec L, Saada-Bouzid E, Fayette J, Dalloz P, Pointreau Y, Caer HL, Falandry C, Digue L, Braccini A, Lopez S, Guillet P, Michel C, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC. Guigay J, et al. Among authors: blot e. Lancet Healthy Longev. 2024 Mar;5(3):e182-e193. doi: 10.1016/S2666-7568(23)00284-2. Lancet Healthy Longev. 2024. PMID: 38432247 Free article. Clinical Trial.
Immunotherapy for colon cancer.
Blot E, Delastre O, Levesque H. Blot E, et al. Lancet. 1999 May 1;353(9163):1524; author reply 1525. doi: 10.1016/S0140-6736(05)75133-3. Lancet. 1999. PMID: 10232339 No abstract available.
Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets.
Gest C, Mirshahi P, Li H, Pritchard LL, Joimel U, Blot E, Chidiac J, Poletto B, Vannier JP, Varin R, Mirshahi M, Cazin L, Pujade-Lauraine E, Soria J, Soria C. Gest C, et al. Among authors: blot e. Cancer Lett. 2012 Apr 28;317(2):207-17. doi: 10.1016/j.canlet.2011.11.026. Epub 2011 Nov 25. Cancer Lett. 2012. PMID: 22120672
CXCR4 membrane expression in node-negative breast cancer.
Blot E, Laberge-Le Couteulx S, Jamali H, Cornic M, Guillemet C, Duval C, Hellot MF, Pille JY, Picquenot JM, Veyret C. Blot E, et al. Breast J. 2008 May-Jun;14(3):268-74. doi: 10.1111/j.1524-4741.2008.00573.x. Epub 2008 Mar 26. Breast J. 2008. PMID: 18373506
57 results